TABLE 1

Patient characteristics

All patientsAt least one contaminated surfacep-value
NoYes
Subjects n301812
Male sex21 (70%)12 (67%)9 (75%)0.70
Age years61 (21–81)58.5 (21–72)64.5 (41–81)0.12
BMI kg·m−229.3 (20.4–48.2)31.1 (23.9–48.2)26.1 (20.4–33.3)0.09
Hypertension14 (50%)10 (56%)4 (33%)0.41
ACE inhibitor use9 (30%)8 (44%)1 (8%)0.05
Hydroxychloroquine use10 (33%)7 (39%)3 (25%)0.69
Immunodeficiency4 (13%)2 (11%)2 (17%)1.00
Lymphopenia <0.7×109·L−112 (40%)4 (22%)8 (67%)0.02
Temperature °C38.0 (36.5–40.2)37.6 (36.5–40.2)38.1 (37.2–40.0)0.16
Diarrhoea2 (7%)0 (0%)2 (17%)0.15
Cough within 24 h from sampling16 (53%)9 (50%)7 (58%)1.00
Respiratory rate breaths per min30 (15–50)30.5 (15–50)30 (22–40)0.72
Ventilation type0.12
 HFNO16 (53%)10 (56%)6 (50%)
 IMV8 (27%)5 (28%)3 (25%)
 NIV3 (10%)3 (17%)0 (0%)
 Standard oxygen mask3 (10%)0 (0%)3 (25%)
Spontaneous breathing during sampling23 (77%)14 (78%)9 (75%)1.00
Oxygen flow the day of sampling#50 (30–60)50 (2–70)50 (5–60)0.79
HRCT abnormalities ≤50% of lung parenchyma18 (64%)12 (75%)6 (50%)0.24
Delay between first symptoms and sampling days11.5 (4–45)11 (4–45)12.5 (4–24)0.34
Delay between hospital admission and sampling days3.5 (1–46)2.5 (1–46)5 (1–13)0.14
Delay between room admission and sampling days2 (0–35)1.5 (0–35)2 (1–13)0.27
Last SARS-CoV-2 CT value of patient before surface swabbing28 (13–39)28 (14–39)27 (13–37)1.00

Data are presented as n (%) or median (range), unless otherwise stated. BMI: body mass index; ACE: angiotensin converting enzyme; HFNO: high-flow nasal cannula oxygenation; IMV: invasive mechanical ventilation; NIV: noninvasive ventilation; HRCT: high-resolution computed tomography; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2. #: n=21; : n=28. Bold text indicates p≤0.05.